Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

NCT07034209 is registered in ClinicalTrials.gov with TJ Biopharma Co., Ltd. as lead sponsor.

NCT NCT07034209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07034209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Lead sponsor
TJ Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2023
Completion date
April 18, 2025
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytoses